Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Numaferm GmbH currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, CIARA A MCKNIGHT, who is also identified as the busiest examiner for the company. Prosecution activity is localized in 1 distinct art unit. Because MCKNIGHT, CIARA A is responsible for 1 busiest examiner pending action, the company's current USPTO activity is focused under a single point of review.
This concentration in 1 distinct art unit means there is no internal baseline for comparing examiner behavior or response times within this portfolio. The presence of 1 pending office action suggests a very specific or early-stage prosecution phase for the company. Practitioners should note that the outcome of this matter depends entirely on the interpretations of one individual within the Biotechnology & Pharmaceuticals sector.
Since the 1 distinct examiner represents the entirety of the pending workload, the prosecution strategy is highly centralized. This requires the applicant to align closely with the specific procedural expectations of CIARA A MCKNIGHT to ensure efficient movement through the system. The data indicates a narrow administrative footprint, which may allow for more direct communication during the examination process for this single pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKNIGHT, CIARA A | 1 | 60.8% | +38.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | MCKNIGHT, CIARA A | 13d |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | MCKNIGHT, CIARA A | 1656 | §102DP | Final Rejection | 13d | Pending | Sep 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial